AstraZeneca, Aventis Post Strong Drug Sales. Results at Firms' Agrochemical Units Contrast
Article Abstract:
First-quarter earnings at AstraZeneca PLC and Aventis S.A. for drugs were up from last year. Agricultural chemicals sales at AstraZeneca were up 6 percent, while Aventis' agrichemical sales were down 6 percent.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Glaxo Wellcome's 1st-half net jumped 19% on strong sales
Article Abstract:
Glaxo Wellcome PLC posted an increase of 19% in its net income for the 2000 first-half. The company, helped by strong sales, posted 1.11 billion pounds (1.79 billion euros) for the period.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Aventis boosts its forecast for year on strength in quarter
Article Abstract:
Aventis SA posted a 68% increase in its net income, earning 163 million euros for the 2nd quarter of 2000. The company is expecting at least a 30% increase in its earnings at the end of the year.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: AstraZeneca shares decline 7.5% despite solid results, rosy outlook. AstraZeneca shares fall 2.5% after cutting sales outlook
- Abstracts: Auna bets on a traditionalist; Chairman Salazar wants to beat Telefonica with networks, not content. Governments Turn To `Golden Shares' To Block Deals
- Abstracts: Progress at PetroChina? Public oil firm aims to strike out on its own. Zhenhai stands to gain from China's oil-sector reforms
- Abstracts: Thomson Multimedia's net profit rises 70% on electronics results. Michelin's provision for restructuring deflates 1999 net
- Abstracts: Gene Therapy Is Showing Promise As a Cancer Fighter. Aventis, Schering-Plough Launch Advanced Trials. Trials on Humans Will Begin for Drug Based on Genes. Human Genome Sciences Extends Lead Over Rivals